Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Dev Biol. 2018 Jan 10;435(1):41–55. doi: 10.1016/j.ydbio.2018.01.005

Fig. 9. Alteration in FLNC aggregation in HSPB7 mutant CMs.

Fig. 9

(A) Filter trap assay probing for Filamin-C in lysates from day 10 hESC-derived cardiomyocytes treated with bafilomycin A shows increase in FLNC-containing aggregates in HPSB7−/− cardiomyocytes compared to wildtype. Shown is a representative image from multiple reproducible experiments. (B) Quantification of filter trap assays. Changes are significant according to an unpaired t-test, corrected for multiple comparisons with the Holm-Sidak method (p<0.0001). (C) Immunofluorescence for cardiac troponin (red) and FLNC (green) in hESC-CMs derived from HSPB7 wildtype or (D) HSPB7 mutant lines following treatment with bafilomycin A. White arrowheads mark representative abnormal puncta.